Related Experiment Videos
The effect of bromocriptine in benign prostatic hypertrophy and vesicosphincteric dynamics
A Matos-Ferreira1, J Corte-Real, J Palma
1University Department of Urology, Curry Cabral Hospital, Lisbon, Portugal.
British Journal of Urology
|August 1, 1987
Summary
Bromocriptine shows promise for benign prostatic hypertrophy (BPH) by improving symptoms, though it does not affect prostate size. Its mechanism appears to involve urethral sphincteric action, not direct effects on the prostate gland itself.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hypertrophy (BPH) is a common condition in aging men.
- Understanding the pharmacological mechanisms for BPH treatment is crucial.
Purpose of the Study:
- To evaluate the efficacy of bromocriptine in patients with benign prostatic hypertrophy (BPH).
- To elucidate the mechanism of action of bromocriptine in BPH and related conditions.
Main Methods:
- Conducted four studies on 66 patients, including a 6-month double-blind placebo-controlled trial of bromocriptine 5 mg/day.
- Performed an open study on acute urinary retention due to BPH.
- Utilized double-blind, controlled urodynamic studies to assess vesicosphincteric dynamics with bromocriptine (2.5 and 5 mg) versus placebo.
Main Results:
- Bromocriptine demonstrated a favorable clinical effect in patients with BPH.
- No significant effect was observed in patients experiencing acute urinary retention due to BPH.
- Urodynamic findings indicated that bromocriptine specifically influences urethral sphincteric mechanisms.
- Prostate weight and volume remained unchanged, suggesting the clinical response is not due to direct prostatic effects.
Conclusions:
- Bromocriptine may offer a therapeutic benefit for benign prostatic hypertrophy (BPH).
- The drug's action is likely mediated through effects on the urethral sphincter, not direct prostatic modification.
- Further research into bromocriptine's role in managing BPH symptoms is warranted.